Epithelial-Mesenchymal Transition is Associated with Altered Immune Composition and Cytotoxic Function in Triple-Negative Breast Cancer
Hanxu LuiD, Meisam BagheriiD, Fred KollingiD, Lucas A. SalasiD, Xiaofeng WangiD, Todd W. MilleriD, Diwakar Ram PattabiramaniD, Brock C. ChristenseniD
Abstract
Epithelial-mesenchymal transition (EMT) is a dynamic process that contributes to breast cancer progression, metastasis, and therapy resistance. EMT also influences the tumor immune microenvironment, shaping immune cell infiltration and function. Although the immunological features of fully epithelial or fully mesenchymal tumor states have been characterized, the immune landscape associated with intermediate or partial EMT states remains poorly understood. To address this gap, we established five single-cell-derived clonal populations from the triple-negative 4T1 mouse mammary tumor cell line, representing a spectrum of EMT phenotypes, and analyzed tumors derived from these clones using single-cell RNA sequencing. We show that tumors derived from these clones retained their relative EMT states in vivo, and that EMT progression is associated with a graded reduction in tumor immunogenicity, accompanied by alterations in immune cell composition and function. Along the EMT spectrum, tumor cells exhibited progressive downregulation of major histocompatibility complex (MHC) class I and II gene expression, along with decreased infiltration of cytotoxic CD8+ T cells, and reduced expression of key effector and trafficking genes (Gzmb, Ccr5, Cxcr6). B cell composition also shifted, with decreased frequencies of IgG1-producing plasma cells and an enrichment of regulatory-like B cells. Natural killer (NK) cells similarly demonstrated progressive functional suppression, marked by reduced expression of cytotoxic molecules and the downregulation of key effector pathways. These findings reveal that EMT is associated with immune cell recruitment and function in a graded manner, providing a rationale for integrating EMT phenotyping into therapeutic strategies to overcome immune resistance in breast cancer.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 2.98
- Field percentile
- top 15%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- CD4 T cells and neutrophils contribute to epithelial-mesenchymal transition in breast cancer
A. Sanlaville, A. Voissiere, … N. Bendriss-Vermare·bioRxiv·Feb 15, 2023
- Inhibition of EMT driver PTK6 enhances anti-tumor immune responses against triple-negative breast cancer
Ibuki Harada, Criseyda Martinez, … Hanna Yoko Irie·bioRxiv·Jan 11, 2025
- Multiple distinct metastatic cell states are induced by epithelial-mesenchymal plasticity
Fahda Alsharief, Robert K. Suter, … Gray W. Pearson·bioRxiv·Aug 15, 2025
- MHC-I downregulation is associated with immune-evasion in breast cancers with heterogeneous activation of epithelial-mesenchymal plasticity
Kimaya M. Bakhle, Andreas Stephanou, … Anushka Dongre·bioRxiv·Oct 19, 2026
- Analysis of Differential Gene Expression and Core Canonical Pathways involved in the Epithelial to Mesenchymal Transition of Triple Negative Breast Cancer Cells by Ingenuity Pathway Analysis.
H. BANERJEE, S. Bhattacharya, S. Ghosh·bioRxiv·Apr 7, 2023
- Primary cilia promote EMT-induced triple-negative breast tumor heterogeneity and resistance to therapy
Camille E. Tessier, Jennifer Derrien, … Vincent J. Guen·EMBO Molecular MedicinePeer-reviewed·Aug 26, 2025